Top Markets
Coin of the day
DelMar Pharmaceuticals, Inc. DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc.

DMPWW
शेयरों में रैंक #42376
Kintara Therapeutics, Inc., previously known as DelMar Pharmaceuticals, Inc.... Kintara Therapeutics, Inc., previously known as DelMar Pharmaceuticals, Inc. until its rebranding in August 2020, operates as a clinical-stage pharmaceutical firm. Headquartered in San Diego, California, and established in 2009, the company is committed to advancing and bringing to market anti-cancer treatments for patients. Its development pipeline includes two advanced therapeutic candidates. One is VAL-083, a DNA-targeting agent poised for Phase III trials, designed to combat various drug-resistant solid tumors such as glioblastoma multiforme, ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The other is REM-001, a late-stage photodynamic therapy intended for conditions like cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and addressing access graft failure in hemodialysis patients. Kintara Therapeutics also maintains a strategic alliance with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. for the manufacturing and commercialization of VAL-083 within the Chinese market.
शेयर मूल्य
$0.005
अंतिम समन्वयन: 2024-06-20
मार्केट कैप
$1.74K
बदलाव (1 दिन)
0.00%
बदलाव (1 वर्ष)
0.00%
देश
US
व्यापार DelMar Pharmaceuticals, Inc. (DMPWW)

श्रेणी

DelMar Pharmaceuticals, Inc. (DMPWW) के लिए P/B अनुपात
2026 को P/B अनुपात TTM: 0
DelMar Pharmaceuticals, Inc. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी का वर्तमान P/B अनुपात (TTM) 0 है। 2026 के अंत में, कंपनी का P/B अनुपात 0 था।
DelMar Pharmaceuticals, Inc. के लिए 2026 से 2026 तक P/B अनुपात का इतिहास
हर वर्ष के अंत में P/B अनुपात
वर्ष P/B अनुपात परिवर्तन
प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।
समान कंपनियों या प्रतिस्पर्धियों के लिए P/B अनुपात
कंपनी P/B अनुपात P/B अनुपात में अंतर देश
6.2613 -
US
6.3483 -
NL
- -
CH
3.634 -
BE
- -
KR